Sham-LP clinical trials

Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)

This study is testing a new medicine called GTX-102 for children with Angelman Syndrome. It will look at how well the medicine helps with thinking skills. Children aged 4 to 17 with a specific type of Angelman Syndrome can take part.